Sharkey, Howes & Javer’s AbbVie ABBV Stock Holding History

Sharkey, Howes & Javer’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-924	Closed	-$67K	–	59
2019 Q2	$67K	Hold	924	–	–	0.03%	103
2019 Q1	$74K	Hold	924	–	–	0.03%	95
2018 Q4	$85K	Hold	924	–	–	0.06%	83
2018 Q3	$87K	Hold	924	–	–	0.05%	91
2018 Q2	$86K	Hold	924	–	–	0.05%	82
2018 Q1	$87K	Hold	924	–	–	0.05%	70
2017 Q4	$89K	Hold	924	–	–	0.05%	70
2017 Q3	$84K	Hold	924	–	–	0.04%	74
2017 Q2	$67K	Hold	924	–	–	0.04%	75
2017 Q1	$60K	Hold	924	–	–	0.03%	83
2016 Q4	$58K	Hold	924	–	–	0.04%	87
2016 Q3	$58K	Hold	924	–	–	0.04%	85
2016 Q2	$57K	Hold	924	–	–	0.04%	87
2016 Q1	$53K	Hold	924	–	–	0.04%	85
2015 Q4	$55K	Hold	924	–	–	0.04%	85
2015 Q3	$55K	Hold	924	–	–	0.04%	87
2015 Q2	$62K	Buy	+924	New	+$60.3K	0.05%	63

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sharkey, Howes & Javer's ABBV Position: Q3 2019 in Review

Sharkey, Howes & Javer sold out of AbbVie (ABBV) in Q3 2019, closing a stake of 924 shares — an estimated $67K sold.

Sharkey, Howes & Javer first reported a position in ABBV in Q2 2015 and held it in 17 quarters. The position peaked at $89K in Q4 2017. 2,003 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

Sharkey, Howes & Javer reported no remaining AbbVie position as of Q3 2019 after selling out during the quarter.
Sharkey, Howes & Javer sold 924 AbbVie shares in Q3 2019, an estimated $67K.
Sharkey, Howes & Javer first reported a position in AbbVie in Q2 2015 and held it in 17 quarters.
Sharkey, Howes & Javer's AbbVie position peaked at $89K in Q4 2017.
2,003 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Sharkey, Howes & Javer's 13F filing for Q3 2019, filed 1 Nov 2019.